肺表面活性物质治疗呼吸窘迫综合征给药方式的研究进展  

Progress in the research on drug delivery method of pulmonary surfactant for treating respiratory distress syndrome

作　　者：闫亚敏[1] 李忆东[1] 龚梅[1] 王志红[1] 

机构地区：[1]上海市儿童医院上海交通大学附属儿童医院,上海200040

出　　处：《国际病理科学与临床杂志》2012年第5期431-436,共6页Journal of International Pathology and Clinical Medicine

摘　　要：肺表面活性物质(pulmonary surfactant,PS)作为一种"救命药"已常规用于新生儿呼吸窘迫综合征的防治,但对急性肺损伤/急性呼吸窘迫综合征的治疗效果仍存在一定的争议。PS的给药方式作为影响其疗效的关键因素受到了医学界的广泛重视,现有的PS给药方法主要有气管导管滴入法、经纤维支气管镜滴入法和超声雾化吸入法,各有优缺点,而操作简便的、非侵袭性的、有效的给药方式是未来继续研究的方向。Pulmonary surfactant（PS） is commonly used as a life-saving strategy in treating respiratory distress syndrome of newborn.However,its efficacy on patients with acute lung injury or acute respiratory distress syndrome is still controversial.The key factor that affects the efficacy of PS is the method for drug delivery.Current methods for PS delivery include instillation through endotracheal intubation or bronchoscopy and ultrasonic atomizing inhalation.All of them display advantages as well as disadvantages.Seeking simple,noninvasive,effective method for PS delivery is the direction for future study.

关 键 词：肺表面活性物质 呼吸窘迫综合征 给药方式 研究进展 

分 类 号：R722.1[医药卫生—儿科]